Literature DB >> 21355776

Second prize: Recurrence rates after percutaneous and laparoscopic renal cryoablation of small renal masses: does the approach make a difference?

Kurt H Strom1, Ithaar Derweesh, Sean P Stroup, John B Malcolm, James L'Esperance, Robert W Wake, Robert Gold, Michael Fabrizio, Kerrin Palazzi-Churas, Xiao Gu, Carson Wong.   

Abstract

BACKGROUND AND
PURPOSE: As radiologic detection of small renal masses increases, patients are increasingly offered percutaneous renal cryoablation (PRC) or transperitoneal laparoscopic renal cryoablation (TLRC). This multicenter experience compares these approaches. PATIENTS AND METHODS: Between September 1998 and May 2010, review of our PRC and TLRC experience was performed. Patients with ≥ 12-month follow-up were included for analysis. Post-treatment surveillance consisted of laboratory studies and imaging at regular intervals. Treatment failure was considered if persistent mass enhancement or interval tumor growth was radiographically evident. Repeated biopsy and re-treatment were recommended in the event of recurrence.
RESULTS: Sixty-one patients underwent PRC and 84 patients underwent TLRC. No significant differences were noted with respect to demographic factors. Mean tumor size was 2.7 ± 1.1 cm (PRC) and 2.5 ± 0.8 (TLRC) cm (P = 0.090). Mean follow-up was 31.0 ± 15.9 months (PRC) and 42.3 ± 21.2 (TLRC) months (P = 0.008), with local tumor recurrence noted in 10/61 (16.4%) PRC and 5/84 (5.9%) TLRC (P = 0.042). For PRC, disease-free survival (DFS) and overall survival (OS) were 93.7% and 88.9%, respectively, with four patients having evidence of disease at last follow-up. DFS and OS were 91.7% and 89.3% for TLRC, with seven patients having evidence of disease at last follow-up. DFS (P = 0.654) and OS (P = 0.939) were similar.
CONCLUSIONS: In this multicenter study of well-matched cohorts, PRC had higher primary treatment failure rates than TLRC. While no differences were noted between DFS and OS, analysis is limited by intermediate follow-up. Further study is necessary to discern reasons for the higher recurrence rates in PRC and to determine what long-term consequences exist.

Entities:  

Mesh:

Year:  2011        PMID: 21355776     DOI: 10.1089/end.2010.0239

Source DB:  PubMed          Journal:  J Endourol        ISSN: 0892-7790            Impact factor:   2.942


  11 in total

1.  The application of PADUA scoring system for predicting complications of laparoscopic renal cryoablation.

Authors:  Junlong Zhuang; Huibo Lian; Xiaozhi Zhao; Gutian Zhang; Weidong Gan; Xiaogong Li; Hongqian Guo
Journal:  Int Urol Nephrol       Date:  2015-03-18       Impact factor: 2.370

2.  Skin-to-tumor Distance Predicts Treatment Failure of T1A Renal Cell Carcinoma Following Percutaneous Cryoablation.

Authors:  Simone L Vernez; Zhamshid Okhunov; Kamaljot Kaler; Ramy F Youssef; Rahul Dutta; Arkadiy Palvanov; Paras Shah; Kathryn Osann; David N Siegel; Igor Lobko; Louis Kavoussi; Ralph V Clayman; Jaime Landman
Journal:  Urology       Date:  2017-06-23       Impact factor: 2.649

3.  Efficacy of percutaneous cryoablation of renal cell carcinoma in older patients with medical comorbidities: Outcome study in 70 patients.

Authors:  Erich K Lang; Kan Karl Zhang; Quan Nguyen; Leann Myers; Mahamed Allaf; Ivan Colon
Journal:  Can Urol Assoc J       Date:  2015 May-Jun       Impact factor: 1.862

Review 4.  Percutaneous image-guided cryoablation: current applications and results in the oncologic field.

Authors:  Roberto Luigi Cazzato; Julien Garnon; Nitin Ramamurthy; Guillaume Koch; Georgia Tsoumakidou; Jean Caudrelier; Francesco Arrigoni; Luigi Zugaro; Antonio Barile; Carlo Masciocchi; Afshin Gangi
Journal:  Med Oncol       Date:  2016-11-11       Impact factor: 3.064

Review 5.  Systematic Review of Contemporary Evidence for the Management of T1 Renal Cell Carcinoma: What IRs Need to Know for Kidney Cancer Tumor Boards.

Authors:  Julie Cronan; Sean Dariushnia; Zachary Bercu; Robert Mitchell Ermentrout; Bill Majdalany; Laura Findeiss; Janice Newsome; Nima Kokabi
Journal:  Semin Intervent Radiol       Date:  2019-08-19       Impact factor: 1.513

Review 6.  Role of tumor location in selecting patients for percutaneous versus surgical cryoablation of renal masses.

Authors:  Christopher J Long; Daniel J Canter; Marc C Smaldone; Tianyu Li; Jay Simhan; Boris Rozenfeld; Ervin Teper; David Y T Chen; Richard E Greenberg; Rosalia Viterbo; Robert G Uzzo; Alexander Kutikov
Journal:  Can J Urol       Date:  2012-10       Impact factor: 1.344

Review 7.  [Focal therapy for small renal masses : Observation, ablation or surgery].

Authors:  J J Wendler; B Friebe; D Baumunk; A Blana; T Franiel; R Ganzer; B Hadaschik; T Henkel; K U Köhrmann; J Köllermann; T Kuru; S Machtens; A Roosen; G Salomon; H P Schlemmer; L Sentker; U Witzsch; U B Liehr; J Ricke; M Schostak
Journal:  Urologe A       Date:  2016-05       Impact factor: 0.639

Review 8.  The contemporary role of ablative treatment approaches in the management of renal cell carcinoma (RCC): focus on radiofrequency ablation (RFA), high-intensity focused ultrasound (HIFU), and cryoablation.

Authors:  Tobias Klatte; Nils Kroeger; Uwe Zimmermann; Martin Burchardt; Arie S Belldegrun; Allan J Pantuck
Journal:  World J Urol       Date:  2014-04-04       Impact factor: 4.226

9.  Renal cryoablation of small renal masses: a Korea University experience.

Authors:  Hyung Keun Kim; Jong Hyun Pyun; Jae Yoon Kim; Seung Bin Kim; Seok Cho; Sung Gu Kang; Jeong Gu Lee; Je Jong Kim; Jun Cheon; Seok Ho Kang
Journal:  Korean J Urol       Date:  2015-02-02

Review 10.  Laparoscopic cryoablation vs. percutaneous cryoablation for treatment of small renal masses: a systematic review and meta-analysis.

Authors:  Kehua Jiang; Kun Tang; Xiaolin Guo; Haoran Liu; Hongbo Chen; Zhiqiang Chen; Hua Xu; Zhangqun Ye
Journal:  Oncotarget       Date:  2017-04-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.